News
BIIB
220.83
-1.64%
-3.68
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Barron‘s · 22h ago
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
NASDAQ · 23h ago
Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals
NASDAQ · 1d ago
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Benzinga · 1d ago
Stoke And Biogen Unveil Long-Term Zorevunersen Data In Dravet Syndrome
NASDAQ · 1d ago
Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention?
Simply Wall St · 1d ago
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
TipRanks · 1d ago
Biogen Price Target Raised to $245.00/Share From $225.00 by Piper Sandler
Dow Jones · 1d ago
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
Benzinga · 1d ago
Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), uniQure (QURE)
TipRanks · 2d ago
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
TipRanks · 2d ago
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Benzinga · 2d ago
Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Disease
NASDAQ · 2d ago
How Biogen’s (BIIB) At-Home LEQEMBI Injections Could Reframe the Alzheimer’s Treatment Investment Story
Simply Wall St · 2d ago
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Barchart · 2d ago
Novartis and Alteogen ink injectable drug delivery deal worth up to $3.2B
Seeking Alpha · 2d ago
Biogen: 4-year Data Support Potential Disease-modifying Effects Of Zorevunersen
NASDAQ · 4d ago
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
TipRanks · 4d ago
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Benzinga · 4d ago
Canada's Drug Agency Backs Public Reimbursement Of Eisai, Biogen's LEQEMBI For Early-Alzheimer's
NASDAQ · 4d ago
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a biotechnology company. The Company is focused on discovering, developing and delivering therapies. It has a portfolio of medicines to treat Multiple Sclerosis (MS), has introduced an approved treatment for Spinal Muscular Atrophy (SMA), co-developed treatments to address a defining pathology of Alzheimer's disease and launched an approved treatment to target a genetic cause of Amyotrophic Lateral Sclerosis (ALS). It markets a drug approved in United States, European Union and certain international markets for the treatment of Friedreich Ataxia (FA) in adults and adolescents aged 16 years and older. It is focused on advancing its pipeline in neurology, specialized immunology and rare diseases. Its marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA, and QALSODY for the treatment of ALS. Its commercialized products also include EMPAVELI and SYFOVRE.